Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 in select tumor types including solid tumors, lymphomas and other hematologic malignancies. Part 3 will determine the tolerated dose of INCB057643 in combination with select SOC agents; and assess the safety and tolerability of the combination therapy in select advanced solid tumors and hematologic malignancies. Part 4 will further evaluate the safety, preliminary efficacy, PK, and PD of the selected dose combination from Part 3 in 4 specific advanced solid tumor and hematologic malignancies.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 5 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 21, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Incyte Corporation
- Interventions being studied
- Drug: INCB057643; Drug: Gemcitabine; Drug: Paclitaxel; Drug: Rucaparib; Drug: Abiraterone; Drug: Ruxolitinib; Drug: Azacitidine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Histologically or cytologically confirmed diagnosis of relapsed or refractory advanced or metastatic malignancies:
- Part 1: solid tumors or lymphomas, or hematologic malignancies
- Part 2: histologically confirmed disease in specific tumor types
- Part 3: advanced solid tumor or hematologic malignancy
- Part 4: select advanced solid tumor or hematologic malignancy
- For Part 1 and 2, subjects must have progressed following at least 1 line of prior therapy and there is no further established therapy that is known to provide clinical benefit (including subjects who are intolerant to the established therapy)
- For Parts 3 and 4, subjects must have progressed following at least 1 line of prior therapy, and the treatment with the select SOC agent is relevant for the specific disease cohort.
- Life expectancy \> 12 weeks, for MF subjects in Parts 3 and 4, life expectancy \> 24 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status
- Parts 1 and 3: 0 or 1
- Parts 2 and 4: 0, 1, or 2
- Willingness to avoid pregnancy or fathering children
- Inadequate bone marrow function per protocol-specified hemoglobin, platelet count, and absolute neutrophil count
- Inadequate organ function per protocol-specified total bilirubin, AST and ALT, creatinine clearance and alkaline phosphatase.
- Receipt of anticancer medications or investigational drugs within protocol-specified intervals
- Unless approved by the medical monitor, may not have received an allogeneic hematopoietic stem cell transplant within 6 months before treatment, or have active graft-versus-host-disease following allogeneic transplant
- Unless approved by the medical monitor, may not have received autologous hematopoietic stem cell transplant within 3 months before treatment
- Any unresolved toxicity ≥ Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapy
- Radiotherapy within the 2 weeks before initiation of treatment. Palliative radiation treatment to nonindex or bone lesions performed less than 2 weeks before treatment initiation may be considered with medical monitor approval
- Currently active and uncontrolled infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
- Untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed
- History or presence of abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful
- Type 1 diabetes or uncontrolled Type 2 diabetes
- HbA1c of ≥ 8% (all subjects will have HbA1c test at screening)
- Any sign of clinically significant bleeding
- Coagulation panel within protocol-specified parameters
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of AlabamaBirmingham, Alabama
- University of CaliforniaLa Jolla, California
- Sarah Cannon Research Institute at Health OneDenver, Colorado
- Yale UniversityNew Haven, Connecticut
- Sylvester Comprehensive Cancer CenterMiami, Florida
- Hematology - Oncology Associates of Treasure CoastPort Saint Lucie, Florida
- University of MichiganAnn Arbor, Michigan
- University of MinnesotaMinneapolis, Minnesota
- Washington UniversitySt Louis, Missouri
- University of Rochester, Wilmot Cancer CenterRochester, New York
- University of North Carolina at Chapel HillChapel Hill, North Carolina
- Wake Forest Baptist HealthWinston-Salem, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 21, 2025. Always confirm current availability with the study team.